Amanda J. Stolarz
Federal Grant PI
Assistant Professor
faculty
Pharmaceutical Science, College of Pharmacy
10 h-index
29 pubs
280 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Amanda J. Stolarz, Assistant Professor in Pharmaceutical Science at the University of Arkansas for Medical Sciences, leads a research group focused on understanding and developing therapies for lymphatic dysfunction, particularly lymphedema. Her work investigates the mechanisms underlying lymphostasis, a condition characterized by impaired lymphatic fluid flow, and explores potential pharmacological interventions.
Her federally funded research, supported by a $368,387 grant from the NIH/National Cancer Institute, specifically targets ryanodine receptors as therapeutic agents to prevent doxorubicin-induced lymphatic dysfunction. This research aligns with her publications examining drug-related lymphedema, the role of endothelial cells in vascular aging and efferocytosis, and the evaluation of animal models for lymphatic disorders. Dr. Stolarz also investigates the real-time evaluation of calcium concentrations and contractility in isolated lymphatic vessels, aiming to elucidate the physiological processes involved in lymphatic function and dysfunction.
Dr. Stolarz collaborates with researchers at the University of Arkansas for Medical Sciences, including Soumiya Pal, Nancy J. Rusch, Ashim K. Bagchi, and Shengyu Mu, contributing to a network of research focused on pharmaceutical sciences and related medical fields. Her scholarship metrics include an h-index of 10, 27 total publications, and 277 total citations.
Metrics
- h-index: 10
- Publications: 29
- Citations: 280
Selected Publications
-
Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema (2025)
-
Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats (2024)
-
Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts (2024)
-
JoVE Video Dataset (2024)
-
Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels (2024)
-
PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging (2023)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Opinion: Endothelial Cells - Macrophage-Like Gatekeepers? (2022)
-
Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels (2022)
-
Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies (2022)
-
Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation (2021)
-
Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy (2021)
Federal Grants 1 $368,387 total
NIH/National Cancer Institute
Contact PI
Aug 2023 - Jul 2028
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
Grants & Funding
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
- Doxorubicin suppression of lymphatic function and therapeutic reversal NIH Co-Investigator
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
Collaboration Network
Top Collaborators
Soumiya Pal
University of Arkansas for Medical Sciences
7 shared publications
In database
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
Showing 5 of 7 shared publications
Nancy J. Rusch
6 shared publications
In database
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Showing 5 of 6 shared publications
Shengyu Mu
University of Arkansas for Medical Sciences
4 shared publications
In database
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Ashim K. Bagchi
University of Arkansas for Medical Sciences
4 shared publications
In database
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- JoVE Video Dataset
- Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
David S. Henry
University of Arkansas for Medical Sciences
3 shared publications
In database
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Sung W. Rhee
University of Arkansas for Medical Sciences
3 shared publications
In database
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Huiliang Zhang
University of Arkansas for Medical Sciences (US)
2 shared publications
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
Zufeng Ding
University of Arkansas for Medical Sciences (US)
2 shared publications
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
Bijay P. Chhetri
2 shared publications
In database
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Michael J. Borrelli
University of Arkansas for Medical Sciences (US)
2 shared publications
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Samir V. Jenkins
University of Arkansas for Medical Sciences
2 shared publications
In database
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Azemat Jamshidi‐Parsian
University of Arkansas for Medical Sciences
2 shared publications
In database
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Joshua H. Phillips
2 shared publications
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
Daniel Fologea
Boise State University (US)
2 shared publications
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
J. Gandy
University of Arkansas for Medical Sciences
2 shared publications
In database
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy
- Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy